Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting

2015 ◽  
Vol 42 (6) ◽  
pp. 1041-1043 ◽  
Author(s):  
Philip J. Mease ◽  
Jane J. Park ◽  
Amit Garg ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell

Rheumatologists are trained to determine the presence of musculoskeletal inflammation through history, physical examination, and if needed, laboratory tests and imaging. However, primary care clinicians, dermatologists, surgeons, and others who may initially see patients with musculoskeletal pain are not necessarily able to make the distinction between inflammatory (e.g., rheumatoid arthritis or psoriatic arthritis) and noninflammatory disease (osteoarthritis, traumatic or degenerative tendonitis, back pain, or fibromyalgia). If such clinicians could more readily suspect and identify possible inflammatory musculoskeletal disease, it would lead to more timely diagnosis and triage to rheumatologists for diagnosis and appropriate management. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been developing evidence-based, practical and reliable criteria that can be used by clinicians to identify inflammatory musculoskeletal disease. The research initiative involves a sequential process of expert clinician nominal group technique, patient focus groups, and Delphi exercises to identify core definitive features of inflammatory disease. The goal is to develop simple clinical criteria (history and physical examination elements) to identify inflammatory arthritis, enthesitis, dactylitis, and spondylitis and distinguish these from degenerative, mechanical, or other forms of these conditions, to achieve more timely and accurate diagnosis and referral of patients with inflammatory arthritis.

2013 ◽  
Vol 40 (8) ◽  
pp. 1442-1445 ◽  
Author(s):  
Philip J. Mease ◽  
Amit Garg ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell

Dermatologist and primary care clinicians are in an ideal position to identify the emergence of psoriatic arthritis (PsA) in patients with psoriasis. Yet these clinicians are not well trained to distinguish inflammatory musculoskeletal disease from other more common problems such as osteoarthritis, traumatic or degenerative tendonitis and back pain, or fibromyalgia. A simple set of clinical criteria to identify inflammatory disease would aid recognition of PsA. At its 2012 annual meeting, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed development of evidence-based, practical, and reliable definitions of inflammatory arthritis, enthesitis, dactylitis, and spondylitis. This project will be a sequential process of expert clinician nominal-group technique, patient surveys and focus groups, and Delphi exercises to identify core features of inflammatory disease, testing these in a small group of patients with and without inflammatory disease, and finally validating these criteria in larger groups of patients.


2014 ◽  
Vol 41 (6) ◽  
pp. 1249-1251 ◽  
Author(s):  
Philip J. Mease ◽  
Amit Garg ◽  
Philip S. Helliwell ◽  
Jane J. Park ◽  
Dafna D. Gladman

Objective.To describe a research project to develop simple clinical criteria to aid in the identification of inflammatory arthritis, enthesitis, dactylitis, and spondylitis and distinguish these from non-inflammatory conditions. The criteria are particularly intended to aid non-rheumatologists, e.g., dermatologists, who need assistance identifying psoriatic arthritis in patients with psoriasis, but may be useful to all clinicians in properly diagnosing rheumatologic conditions.Methods.The proposed research methodology includes the use of a nominal group exercise among expert clinicians and patient focus groups, Delphi exercises among clinicians and patients, application of criteria test sets to a small group of representative patients with inflammatory and non-inflammatory musculoskeletal conditions, and validation by application of optimal criteria sets to large groups of patients with inflammatory and noninflammatory conditions.Results.Examples of elements to describe inflammatory conditions derived from a nominal group exercise conducted at the 2013 GRAPPA annual meeting are described, along with planned project activities.Conclusion.This project will lead to the development of practical criteria to aid in the diagnosis and appropriate clinical care of patients with chronic inflammatory musculoskeletal conditions.


2017 ◽  
Vol 44 (10) ◽  
pp. 1445-1452 ◽  
Author(s):  
William Tillett ◽  
Emma Dures ◽  
Sarah Hewlett ◽  
Philip S. Helliwell ◽  
Oliver FitzGerald ◽  
...  

Objective.To rank outcomes identified as important to patients with psoriatic arthritis (PsA) and examine their representation in existing composite measures.Methods.Seven nominal group technique (NGT) meetings took place at 4 hospital sites. Two sorting rounds were conducted to generate a shortlist of outcomes followed by a group discussion and final ranking. In the final ranking round, patients were given 15 points each and asked to rank their top 5 outcomes from the shortlist. The totals were summed across the 7 NGT groups and were presented as a percentage of the maximum possible priority score.Results.Thirty-one patients took part: 16 men and 15 women; the mean age was 54 years (range 24–77; SD 12.2), the mean disease duration was 10.3 years (range 1–40; SD 9.2), and mean Health Assessment Questionnaire was 1.15 (range 0–2.63; SD 0.7). The highest-ranked outcomes that patients wished to see from treatment were pain with 93 points (20.0%), fatigue 62 (13.3%), physical fitness 33 (7.1%), halting/slowing damage 32 (6.9%), and quality of life/well-being 29 (6.2%). Reviewing existing composite measures for PsA demonstrated that no single measure adequately identifies all these outcomes.Conclusion.Pain and fatigue were ranked as the outcomes most important to patients receiving treatment for PsA and are not well represented within existing composite measures. Future work will focus on validating composite measures modified to identify outcomes important to patients.


Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Hema Chaplin ◽  
Ailsa Bosworth ◽  
Jessica Meehan ◽  
Rona Moss-Morris ◽  
Heidi Lempp ◽  
...  

Abstract Background/Aims  Patients who do not achieve sustained low disease activity despite drug treatments are referred to as having refractory disease. However, usage of this term varies and often does not account for any discrepancy between inflammation and persistent symptoms, adult or juvenile onset nor differences between patients’ and healthcare professionals’ perspectives. The study aimed to explore and achieve consensus on a definition of refractory disease across healthcare professionals and patients, through a mixed-methods Delphi approach. Methods  Three rounds of voting (one face-to-face nominal group (n = 13), and two online rounds (ns = 40 and 53)) were conducted, in conjunction with the National Rheumatoid Arthritis Society. Participants voted on the inclusion and relevance of statements to generate a broader definition of refractory disease, derived from previous qualitative interviews with multi-disciplinary healthcare professionals and patients (adult and juvenile onset), a systematic review of current definitions and health psychology theory. The process involved voting on: a) name preferences, b) treatment and inflammation statements, c) domains for inclusion regarding symptoms and impact, and d) rating of individual components within each domain, including relevance to: i) Refractory Arthritis and ii) Disease Flare for discriminatory validity. A predetermined cut off was applied to identify which domains needed to be included, until final consensus was reached. Full NHS ethical approval was granted (London-Hampstead-18/LO/1171). Results  With minimal attrition (n = 3 in both online rounds), 106 international participants including Patient Representatives, Rheumatologists, Nurses, GPs, Psychologists, Physiotherapists, Researchers, Pharmacist, Podiatrist, Occupational Therapist and a Social Worker participated. Refractory Inflammatory Arthritis was the most popular name, (25% of votes) followed by Persistent Inflammatory Arthritis (19% of votes) hence its application in the presence (Persistent Inflammation) or absence (Persistent Symptoms) of inflammation as part of the definition. Regarding treatment and inflammation, these were voted in the majority to be kept broad rather than specifying rigid cut-offs. From the original 73 components across 10 domains identified to capture symptoms and impact, initial analysis has resulted in six domains reaching consensus for inclusion. These domains cover: 1) Disease Activity, 2) Joint Involvement, 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) cs/b/tsDMARD Experiences. Within these, 18 components were identified as related and important e.g. One or two persistently active/affected joints, Reduced mobility, Disease-related Distress, Inability to perform desired activities, Repeated need of short course steroids and Disease Activity not captured by DAS28. These capture the multi-faceted presentation and experience of Refractory Inflammatory Arthritis in these two populations. Conclusion  A broader definition for refractory inflammatory arthritis has been generated through a Delphi method to capture the experiences of rheumatologists, patients and multi-disciplinary healthcare professionals. This definition needs further refinement and validation to assess clinical and research utility to identify high risk patients with unmet needs. Disclosure  H. Chaplin: None. A. Bosworth: None. J. Meehan: None. R. Moss-Morris: None. H. Lempp: None. S. Norton: None.


2010 ◽  
Vol 11 (2) ◽  
pp. 173-209 ◽  
Author(s):  
Willem Karel M. Brauers ◽  
Romualdas Ginevičius

The definition of robustness in econometrics, the error term in a linear equation, was not only broadened, but in addition moved to the meaning of common language: from a cardinal to a qualitative one. At that moment the most robust Multi‐Objective Optimization Method has to fulfill seven essential conditions. In addition, considering all stakeholders involved, the choice of the objectives is non‐subjective with the assistance of the Ameliorated Nominal Group Technique and the Delphi method. Outside Normalization is not necessary by the use of a Full Multiplicative Form or of MOORA (Multi‐Objective Optimization by Ratio Analysis). This last one is composed of ratio analysis “senso stricto” and of the Reference Point Method with the previously obtained ratios as a starting point. Combining the three methods in MULTIMOORA a full guarantee for robustness in Multiple Objectives Optimization is offered. This interpretation is tested by an application to the Economy of the Belgian Regions. Santrauka Stiprumo apibrežimas ekonometrijoje, klaidos terminas linijineje lygtyje buvo ne tik išplestas, jo reikš‐me buvo perkelta i paprasta kalba, t. y. nuo kiekybines iki kokybines reikšmes. Šiuo metu stipriausi daugiatiksliai optimizavimo metodai turi atitikti septynias pagrindines salygas. Be to, turint omenyje visas suinteresuotas grupes, tikslu pasirinkimas yra objektyvus taikant patobulinta nominaliu grupiu ir Delphi metodus. Normalizavimas privalo būti taip pat objektyvus, tai imanoma padaryti naudojant dauginamaja MOORA (daugiatikslis optimizavimas remiantis santykio analize) metodo forma. Ji su‐sideda iš santykio analizes "senso strigto” ir atskaitos taško metodo su anksčiau gautu santykiu kaip pradžios tašku. Taigi sujungus tris metodus, kaip stiprumo garantas buvo pasiūlytas MULTIMOORA. Šis metodas yra išbandytas tiriant Belgijos regionu ekonomika.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 130.2-130
Author(s):  
Q. Dumoulin ◽  
X. Matthijssen ◽  
F. Wouters ◽  
A. Van der Helm - van Mil ◽  
E. Niemantsverdriet

Background:Pain in metacarpophalangeal (MCP)-joints in patients presenting with clinically suspect arthralgia (CSA) is one of the clinical features by which patients are considered at risk for progression to inflammatory arthritis (IA). As such this symptom is characteristic for CSA and therefore part of a list of clinical parameters determined by an EULAR-taskforce to identify a more homogeneous group of patients within CSA (the EULAR definition of arthralgia suspicious for progression to RA). MRI-detected subclinical inflammation is known to be present in patients with CSA. In general, arthralgia in CSA can be explained by this subclinical inflammation, however to date, the association of subclinical inflammation with pain in MCP-joints specifically is not clear. Subsequently, it is unknown whether this association differs pertinently when investigated with self-reported pain, or with pain in the form of tenderness at physical examination.Objectives:This study will investigate whether MCP-pain and MCP-joint tenderness are associated with MRI-detected subclinical inflammation in patients with CSA, and more specifically those who have progressed to IA.Methods:Between April 2012- February 2019, 602 patients were consecutively included in the Leiden clinically suspect arthralgia (CSA)-cohort. Follow-up ended when patients developed clinically apparent IA (determined at physical examination), or else after 2-years (median follow-up time 25 months). MCP-joints were assessed for self-reported joint pain by the patient using a mannequin and subsequently for joint tenderness by physical examination. Baseline unilateral MRIs of the MCP (2-5)-joints were scored by two readers, blinded for clinical data, on subclinical inflammation (synovitis, tenosynovitis, osteitis). Associations between MCP-pain or MCP-joint tenderness and MRI-detected subclinical inflammation were studied at patient level by logistic regression analyses, entering the mentioned MRI-detected features separately (univariable) and together (multivariable).Results:33% of 227 patients with self-reported MCP-pain had MRI-detected subclinical inflammation and 38% of 226 patients with MCP-joint tenderness had MRI-detected subclinical inflammation. Self-reported MCP-joint pain was univariable associated with subclinical inflammation and synovitis in particular (OR 2.00, 95% CI: 1.21-3.30, OR 2.87, 95% CI: 1.29-6.39). In multivariable analysis this MCP-pain was associated with synovitis (OR 2.54, 95% CI: 1.12-5.77). MCP-joint tenderness was univariable associated with subclinical inflammation, and synovitis and tenosynovitis in particular (OR 1.84, 95% CI: 1.29-2.63, OR 1.76, 95% CI: 1.10-2.81, OR 1.69, 95% CI: 1.12-2.55, respectively). In multivariable analysis, tenosynovitis remained significant (OR 1.54, 95% CI: 1.00-2.36). Of all patients with self-reported MCP-joint pain who developed IA, 50% had MRI-detected subclinical inflammation. For MCP-joint tenderness this was 61%. Patients with MCP-joint tenderness without subclinical inflammation who developed IA, developed clinical arthritis at a joint that was not scanned (85%), hence they may have had subclinical inflammation that was not imaged. The other 15% did develop arthritis in an MCP-joint, suggesting that subclinical inflammation developed after CSA-onset.Conclusion:Arthralgia in the MCP-joints is associated with subclinical inflammation in CSA, in particular with synovitis and tenosynovitis. The prevalence of subclinical inflammation is highest for tender joints at physical examination; this can be acknowledged when applying the EULAR definition of arthralgia suspicious for progression to RA.Disclosure of Interests:None declared


2012 ◽  
Vol 39 (2) ◽  
pp. 415-417 ◽  
Author(s):  
PHILIP J. MEASE

The most widely applied criteria for classifying psoriatic arthritis (PsA) are the CASPAR (ClASsification of Psoriatic ARthritis) criteria. A patient who fulfills the CASPAR criteria must have evidence of inflammatory arthritis, enthesitis, or spondylitis, and may have an inflammatory musculoskeletal component, dactylitis. Although the criteria were developed by rheumatologists, not all patients with PsA are seen by rheumatologists. Thus, it is important for clinicians such as dermatologists, primary care providers, physiatrists, and orthopedists, and patients themselves, to be able to recognize the presence of inflammatory musculoskeletal disease and distinguish it from degenerative or traumatic musculoskeletal disease. At their 2010 annual meeting, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed the steps they are taking to define the key variables that must be present to distinguish inflammatory arthritis, enthesitis, and dactylitis from degenerative, traumatic, mechanical, or infectious forms of these conditions.


Folia Medica ◽  
2015 ◽  
Vol 57 (2) ◽  
pp. 127-132
Author(s):  
Radost S. Assenova ◽  
Jean Yves Le Reste ◽  
Gergana H. Foreva ◽  
Daniela S. Mileva ◽  
Slawomir Czachowski ◽  
...  

Abstract INTRODUCTION: Multimorbidity is a health issue with growing importance. During the last few decades the populations of most countries in the world have been ageing rapidly. Bulgaria is affected by the issue because of the high prevalence of ageing population in the country with multiple chronic conditions. The AIM of the present study was to validate the translated definition of multimorbidity from English into the Bulgarian language. MATERIALS AND METHODS: The present study is part of an international project involving 8 national groups. We performed a forward and backward translation of the original English definition of multimorbidity using a Delphi consensus procedure. RESULTS: The physicians involved accepted the definition with a high percentage of agreement in the first round. The backward translation was accepted by the scientific committee using the Nominal group technique. DISCUSSION: Some of the GPs provided comments on the linguistic expressions which arose in order to improve understanding in Bulgarian. The remarks were not relevant to the content. The conclusion of the discussion, using a meta-ethnographic approach, was that the differences were acceptable and no further changes were required. CONCLUSIONS: A native version of the published English multimorbidity definition has been finalized. This definition is a prerequisite for better management of multimorbidity by clinicians, researchers and policy makers.


2012 ◽  
Vol 39 (11) ◽  
pp. 2214-2215 ◽  
Author(s):  
AMIT GARG ◽  
DAFNA D. GLADMAN ◽  
PHILIP J. MEASE

At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed the need to develop a framework for defining inflammatory arthritis, enthesitis, dactylitis, and spondylitis, particularly as they relate to psoriatic arthritis (PsA). GRAPPA members first addressed this subject at their 2010 meeting, where the CASPAR (ClASsification of Psoriatic ARthritis) criteria were discussed. Although these are classification criteria, the CASPAR are also often applied as a diagnostic measure by clinicians screening for PsA, particularly its core criterion: recognizing the presence of inflammatory musculoskeletal disease. In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA.


2017 ◽  
Vol 44 (10) ◽  
pp. 1522-1528 ◽  
Author(s):  
Ana-Maria Orbai ◽  
Maarten de Wit ◽  
Philip J. Mease ◽  
Kristina Callis Duffin ◽  
Musaab Elmamoun ◽  
...  

Objective.To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).Methods.At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants.Results.We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient’s global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda.Conclusion.The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.


Sign in / Sign up

Export Citation Format

Share Document